- Home
- SAGE
as 02-21-2025 4:00pm EST
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 444.1M | IPO Year: | 2014 |
| Target Price: | $10.67 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Hold | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.62 - $23.22 | Next Earning Date: | 02-11-2025 |
| Revenue: | $41,243,000 | Revenue Growth: | -52.30% |
| Revenue Growth (this year): | 123.13% | Revenue Growth (next year): | 69.65% |
Latest Sage Therapeutics Inc. News
SAGE Breaking Stock News: Dive into SAGE Ticker-Specific Updates for Smart Investing
TipRanks
9 days ago
Sage Therapeutics price target lowered to $12 from $14 at Scotiabank
Zacks
10 days ago
Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y
Thomson Reuters StreetEvents
10 days ago
Q4 2024 SAGE Therapeutics Inc Earnings Call
GuruFocus.com
11 days ago
Sage Therapeutics Inc (SAGE) Q4 2024 Earnings Call Highlights: Strong Prescription Growth Amid ...
Zacks
11 days ago
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates
Business Wire
11 days ago
Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates
Zacks
18 days ago
Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for
Zacks
23 days ago
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics
Compare SAGE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SAGE Sage Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.